Matthew Dankner considers how CIRBP pathway might be targetable and the status of the research

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, considers how the cold-inducible RNA binding protein (CIRBP) pathway might be targetable and the status of the research leading to potential clinical application.

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, considers how the cold-inducible RNA binding protein (CIRBP) pathway ...

Matthew Dankner explains how CIRBP was identified as important to invasive cells in brain metastases

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, explains how Cold-inducible RNA binding protein (CIRBP) was identified as important to the growth of highly invasive cells in brain metastases.

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, explains how Cold-inducible RNA binding protein (CIRBP) was identified ...

Matthew Dankner describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes a double blinded analysis of 164 brain metastases patients characterized by minimally or highly invasive characteristics supporting the principle of invasive histopathology, the risk of local recurrence, and the impact on survival.

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes a double blinded analysis of 164 brain metastases ...

Matthew Dankner describes how the concept of invasive histopathology relates to brain metastases

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes how the concept of invasive histopathology provides an alternative theory to the spilling of cancer cells and the recurrence of brain metastases after resection

Matthew Dankner, MD/PhD student, Research Program in Cancer Metastases, McGill University, describes how the concept of invasive histopathology provides an ...

David Roberge, MD, examines why individuals may prefer SRS while others may would opt for WBRT

Dr. Roberge, Head of Radiation Oncology, University of Montreal, examines why individuals may prefer stereotactic radiotherapy (SRS) while others may would opt for whole brain radiation treatment (WBRT).

Dr. Roberge, Head of Radiation Oncology, University of Montreal, examines why individuals may prefer stereotactic radiotherapy (SRS) while others may ...

David Roberge, MD, discusses how COVID-19 affected enrollment in the CE.7 clinical trial

Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how the trial was amended, and expectations for how COVID-19 will impact the completion of the trial.

Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how ...

David Roberge, MD, explains rationale for the design of the CE.7 trial

Dr. Roberge, Head of Radiation Oncology, University of Montreal, explains rationale for the design of the CE.7 trial requiring both hippocampal avoidance and treatment with memantine in the WBRT arm and why it may be relevant to coprimary endpoint and secondary endpoints.

Dr. Roberge, Head of Radiation Oncology, University of Montreal, explains rationale for the design of the CE.7 trial requiring both ...

David Roberge, MD, describes rationale for cross-border CE.7 trial in patients with brain metastases

Dr. Roberge, Head of Radiation Oncology, University of Montreal, describes the rationale for the cross-border CE.7 trial enrolling patients with 5 or more brain metastases compared to numerous trials comparing stereotactic radiotherapy (SRS) to whole brain radiation treatment (WBRT) with patients with four or fewer brain metastases.

Dr. Roberge, Head of Radiation Oncology, University of Montreal, describes the rationale for the cross-border CE.7 trial enrolling patients with ...

Raymond Sawaya, MD, considers definitive clinical trial outcomes and non-invasive treatment

Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, considers the definitive clinical trial outcomes in certain cancer types and the application of non-invasive treatment for brain metastases.

Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, considers the definitive clinical trial outcomes in ...

Raymond Sawaya, MD, discusses the addition of patients with brain metastases to clinical trials

Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses cancer patients with brain metastases, who have historically been excluded from clinical trials, how this has changed, and criteria that make brain metastases clinical trials unique.

Dr. Sawaya, Chairman, Department of Neurosurgery, University of Texas MD Anderson Cancer Center, discusses cancer patients with brain metastases, who ...